The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
It should be taken into consideration that auto-antibodies (auto-Abs) against type I IFNs have been adverted in some patients. Whereas the severity of COVID-19 was recognized due to neutralizing auto-Abs against type I IFNs among 10% of patients. In such cases, treatment with IFN-? is less effective and it should be redirected to IFN-ß therapy
I have invested in a number of lithium mining companies, none have a mining community on the door step, the work force is the biggest asset , miners are born into this work and are full of pride,
They will be raring to go . That s the biggest strength of this venture
Blencowe resources and spreader does make you wonder companies with great potential head in one direction , Gibraltar
My wife is a teaching assistant special needs, she has just had her second AZ vaccine , she has tests weekly ,also blood tests monthly, the NHS will will soon have a bank of data on all vaccines Showing antibodies , getting people onboard , like we have seen with synairgen. Is the biggestTrial
We as shareholders. Are relying on people to test our drug, I hope we have all had the vaccine when offered, I had a cousin with polio, thank science . That has now nearly gone away
I have the flu jab every year, I have never seen data on how successful the vaccine is or the pneumonia vaccine which I had several years ago, you wold of thought the U.K. gov would of been well ahead of the world in all elements of the vaccination programmes .